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Polymeric nanoparticles have received great attention as potential
controlled drug delivery systems. Biodegradable polymers has been
extensively used in the development of these drug carriers, and
the polyesters such as polylactic acid, polyglycolic acid and their
copolymers as poly-lactide-co-glycolide are the most used,
considering its biocompatibility and biodegradability. Thermal
analysis techniques have been used for pharmaceutical substances
for more than 30 years and are routine methods for screening drug-
excipient interactions. The aim of this work is to use thermal
analysis to characterize PLGA nanoparticles containing a
hydrophobic drug, praziquantel. The results show that the drug is
in an amorphous state or in disordered crystalline phase of
molecular dispersion in the PLGA polymeric matrix and that the
microencapsulation process did not interfere with the chemical
structure of the polymer, mantaining the structural drug integrity.
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Nanoparticles are considered one of the most
promising dosage forms as potential formulations for site-
specific drug delivery system including drug targeting
(Mainardes, Silva, 2004; Hans, Lowman, 2002). Colloidal
polymeric particles used as drug carriers can be made of
artificial or natural polymers, which must be biocompatible
(Soppimath et al., 2001; Gorner et al., 1999). In the past
two decades, many works have been carried out in order to
apply biocompatible and/or biodegradable polymers in
drug delivery systems (Jain, 2000).
Nanoparticles are a collective name for nanospheres
and nanocapsules. Nanospheres have a matrix type
structure, where active compounds can be adsorbed on their
surface, entrapped or dissolved into the matrix.
Nanocapsules have a polymeric shell and an inner core. In
this case, the active substances are usually dissolved in the
core, but may also be adsorbed on their surface (Allemann
et al., 1998; Panyam, Labhasetwar, 2003).
Although a number of different polymers have been
investigated for formulating biodegradable nanoparticles,
polymers of poly(L-lactic-acid) (PLA) and their
copolymers with glycolic acid (PLGA) have been
extensively used in controlled drug delivery systems. The
lactide/glycolide polymers chains are cleaved by hydrolysis
to form natural metabolites (lactic and glycolic acids),
which are eliminated from the body through the citric acid
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cycle. PLGA provides a wide range of degradation rates,
from months to years, depending on its composition and
molecular weight (Mainardes, Evangelista, 2005; Uhrich
et al., 1999; Vert et al., 1998; Anderson, Shive, 1997;
Burkersroda et al., 2002).
Aliphatic polyesters are polymers of the poly(α-
hidroxy) acids class, one of the polymers families more
attractive and promising, because their members are
biocompatible and bioresorbable and could be used in several
applications in the medicinal area (Iannace et al., 1994). The
presence of the ester linkage makes these polymers
hydrolytically unstable, this means that they can be degraded
when in contact with the corporal fluids, resulting in products
that are reabsorbed by the organism, as part of the
carbohydrates metabolism (Beiser, Kanat, 1990). In the last
years, the biodegradable polymers have gained a growing
importance in the medical area. They have been used in a wide
number of applications in the human body, such as surgical
sutures, controlled drug release systems, artificial skins, guides
for nerves, veins and artificial arteries and orthopedic devices
(Langer et al., 1990). Usually, for polymers to be used as
biomaterials, it is necessary to satisfy a series of requirements,
not always found in only one polymer. The degradation rate of
the aliphatic polyesters in vitro and in vivo was investigated by
several authors (Holland, Yasin, 1986; Vert, Garreau, 1991;
Dumitriu, 1996; Lindhardt, 1998). It is known that the molar
mass,  polydispersion, crystalline degree, morphology, thermal
history and chemical structure of the polymers are factors that
influences considerably the degradation rate (Dumitriu, 1996).
Polymers with lower molar mass degrade faster than those
with higher molar mass (Lindhardt, 1998) and the branched
polymers degrade faster than the linear ones. However, the
mechanism of the degradation is not totally understood.
When working with biodegradable polymer systems,
the selection of appropriate techniques of characterization
is an important step to assure a reproducible and effective
product. Biodegradable polymers have several physical and
chemical characteristics, such as molecular mass average
and distribution, glass transition and/or melting
temperatures, monomer ratios and sequencing for
copolymers. All these properties can influence the physical
behavior of raw polymers (Hausberg, Deluca, 1995).
The mobility of a polymeric chain determines the
physical characteristics of the final product. The mobility
is a function of atoms agitation in the molecules, being
directly proportional to the temperature. Therefore, the
knowledge of the physicochemical characteristics of a
polymer is fundamental to understand its
thermomechanical performance (Canevarolo, 2002).
When polymers are used as controlled drug delivery
systems, additional qualities, such as surface area, bulk
density, surface morphology and particle size are included
and may affect both degradation and drug release from the
polymeric system. This requires analysis of these properties
for a complete understanding and eventual prediction of the
system’s behavior (Hausberg, Deluca, 1995).
Thermoanalytical methods, such as DSC and DTA,
are of great usefulness for  polymers analysis, and they
have been also used to investigate interactions between
polymer and drugs in several formulations of micro- and
nanoparticles (Gamisans et al., 1999; Calvo et al., 1996).
Useful information can be obtained regarding the
crystalline morphology of the polymer and the state of solid
or molecular dispersion of the associated drug to these
polymeric systems (Magenhein, Benita, 1991; Schaffazick
et al., 2003). DSC analyses have been also used to study
the intermolecular interactions between drugs and
pharmaceutical adjuvants. They are of great usefulness in
pre-formulation studies, because information about the
physical potential or chemical incompatibilities between
drug and adjuvants can be obtained (Marini et al., 2003).
It is also possible to investigate chemical reactions, such as
polymerization and degradation. In particular, DSC allows
a rapid evaluation of possible incompatibilities by revealing
changes in the appearance, shift or disappearance of
melting or other endothermic and/or exothermic processes,
and/or variations in the corresponding enthalpies reactions
(Schaffazick et al., 2003). Additional information
regarding the effects of storage at high temperatures can
also be obtained (Araujo et al., 2003). The development of
new dosage forms is facilitated by the use of thermal
methods for characterization of pharmaceutical
preparations with the direct application to the quality
control (Ford, Timmins, 1986).
Thus, the goal of this work was to apply thermal
analysis to characterize biodegradable nanoparticles




The polymer studied was: Poly(D,L-lactide-co-
glycolide) (PLGA), with a copolymer ratio of DL-lactide
to glycolide of 50:50 (MW 40,000-100,000 g/mol) (Sigma
Chemical CO, USA). The surfactant used was poly(vinyl
alcohol) (PVA) (Sigma Chemical CO, USA). The organic
solvent was methylene chloride (Labsynth Ltda., Brazil).
Distilled water of Milli-Q quality was used. The model
encapsulated drug was praziquantel (PRZ) (Henrifarma,
Brazil).
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Methods
Nanoparticles preparation
The nanoparticles, loaded or not with praziquantel
(PRZ), were prepared by an emulsion-solvent evaporation
method. Typically, a solution of PLGA in a determined vo-
lume of methylene chloride containing or not PRZ (10-30%
w/w) was mixed with a 0.7% (w/v) PVA aqueous solution.
This mixture was homogenized for 1 min by vortex and then
sonicated using a microtip probe sonicator set at 55 W of
energy output (XL 2002 Sonicator® ultrasonic liquid
processor) during 20 min to produce the oil-in-water
emulsion. The organic phase was evaporated during 20 min
on a rotative evaporator under partial vacuum. The
nanoparticles were recovered by ultracentrifugation (21,000
rpm, 25 min, Hitachi). The nanoparticles were washed twice
with water in order to remove traces of PRZ eventually
adsorbed on the surface. The washing solutions were
eliminated by a further centrifugation as described above.
The purified nanoparticles were freeze-dried for 24 h.
Morphology
The morphology of the nanoparticles was
investigated by scanning electron microscopy (SEM)
(JEOL JSM- T330A). The nanoparticles were fixed on
supports and coated with gold under an argon atmosphere
using a gold sputter module in a high-vacuum evaporator.
Observation was performed by 10 and 20 kV.
Determination of PRZ loading
The amount of PRZ entrapped into the nanoparticles
was determined in triplicate by HPLC with the UV
detection set at 262 nm (Varian ProStar 330). A reversed
phase Lichrospher C18 column (240 x 4 mm i.d., pore size
5 µm) was used. The mobile phase consisted of a mixture
of acetonitrile:water (3:2 v/v) and the flow rate was set at
1 ml/min. The freeze-dried nanoparticles (20 mg) were
dissolved in methylene chloride (5 mL) (direct method) and
vortexed for 15 min. After eventual dilutions in  mobile
phase, the solution was injected and the drug concentration
was obtained by means of a analytical curve previously
constructed. Before injection, all solutions were previously
filtered through a membrane filter (pore size 0.22 µm,
Millipore).
Differential Scanning Calorimetry (DSC)
The physical state of PRZ inside the nanoparticles was
characterized by the analysis of the DSC curves. The curves
were obtained in a DSC cell (Mettler, SW 7.01) using
aluminium crucibles with about 2 mg of samples, under
dynamic air atmosphere (100 mL/min) and heating rate of
20 °C/min at a temperature range from 25 to 600 °C. DSC
cell was calibrated with indium (m.p. 156,6 °C; AHfus=
28,54 J/g) and zinc (m.p. 419.6 °C). DSC experiments with
pure PRZ were previously carried out to identify the melting
point peak. As a control, physical mixtures of PRZ and
PLGA were also analyzed. Subsequently, nanoparticles with
a theoretical loading rate of 10% of PRZ were analyzed, as
required by the sensitivity of the apparatus.
Simultaneous TG-DTA
The thermal stability of the samples was verified by
simultaneous TG and DTA, using a SDT 2960 system (TA
INSTRUMENTS). TG-DTA curves were obtained in the
temperature range from 30 to 800 °C, using aluminium
crucibles with about 8 mg of samples, under dynamic air
atmosphere (100mL/min) and heating rate of 20 °C/min.
Fourier Transform Infrared (FTIR) Studies
Fourier transform infrared (FTIR, SHIMADZU,
FTIR-8300) analysis was conducted to verify the
occurrence of chemical bonds between drug and polymer.
The samples were scanned in the IR range from 500 to
4000 cm-1 and carbon black was used as reference. The
detector was purged carefully with clean dry helium gas to
increase the signal level and reduce moisture.
RESULTS AND DISCUSSION
Nanoparticles morphology
The emulsion-solvent evaporation process produced
nanoparticles successfully, as can be seen in Figure 1. The
particles showed sub-micrometric size, fine spherical
shape, without any aggregation or adhesion.
Determination of PRZ loading
The incorporation of PRZ into PLGA nanoparticles
FIGURE 1 - SEM images of PRZ-nanoparticles.
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was examined. Maintaining a constant initial mass
polymer, the mass of PRZ was varied from 10 to 30% in
relation to polymer mass. The encapsulation efficiency of
the nanoparticles is illustrated in Table I. A direct relation
between  encapsulation efficiency and theoretical PRZ
loading was not observed. As can be seen, the higher
encapsulation (88%) was obtained with a theoretical drug
loading of 10%.
Thermal analysis
Figure 2 show DSC curves, which provided
qualitative and quantitative information about the physical
state of the drug in the nanoparticles and in the control
samples, i. e. the pure drug and the physical mixture of PRZ
and PLGA.
The pure PRZ (Curve B, Figure 2) shows a sharp
endothermic peak that corresponds to melting at 143 °C,
indicating its crystalline nature. After melting (from
250 °C), two exothermic peaks are observed due to the
thermal decomposition of the drug, with maximum
temperatures around 400 and 560 °C. These data are
confirmed by the TG-DTA curve of pure PRZ (Figure 3 D),
which in addition shows that the maximum weight loss
(99.99%) occurs in 366 °C.
The pure PLGA exhibit an endothermic event (60 °C)
referring to the relaxation peak that follow the glass
transition (Curve A, Figure 2). No melting point was
observed, because PLGA appears amorphous in nature.
The exothermic peaks in 370, 400 e 500 °C are related to
the thermal decomposition of the polymer. The decom-
position, characterized by an endothermic event, has begun
at approximately 320 °C. The TG-DTA curves of pure
PLGA (Figure 3 A) shows that the polymer presents
thermal stability until 250 °C. The weight loss of pure
PLGA, attributed to thermal decomposition, occurs in two
steps (390 °C-96.60% and 470 °C-3.18%).
The DSC curves of PRZ and PLGA physical mixture
(Curve C, Figure 2) showed peaks resulting from simple
superposition of the DSC curves of the separated
components. Thus, none interaction could be attributed to
the heating process.
The relaxation peak of empty nanoparticles was the
same of the pure PLGA (60 °C) (Curve D, Figure 2). The
thermal decomposition of empty nanoparticles has begun in
a lower temperature (220 °C) than that of the pure polymer
(320 °C). The nanoparticles are more exposed to the thermal
degradation because their sub-micrometric size makes the
superficial area larger. In relation to the polymer, since the
nanoparticles show wider superficial area they degrade
easier. It was not observed an endothermic peak in
approximately 350 °C, that seem to be characteristic of
PLGA (Curve A, Figure 2 and Curve C, Figure 2),
confirming the previous data that shows PLGA nanoparticles
to have lower thermal stability than pure polymer.
The DSC curve of PRZ-containing nanoparticles
(Curve E, Figure 2) shows the event corresponding to the
relaxation enthalpy of polymer (60 °C). It can be observed
that the microencapsulation process did not affect the
polymer structure because the pure polymer presented the
same value for relaxation enthalpy. The thermal
decomposition of PRZ-containing particles begins
approximately at the same temperature as the empty
particles (200 °C), but the exothermic event was more
intense, because the decomposition refers to both polymer
and drug. The DSC study did not detect any crystalline
drug material in the PRZ-loaded nanoparticles samples; the
endothermic peak of PRZ was absent. Thus, it can be
concluded that the drug incorporated into the nanoparticles
was in an amorphous or disordered-crystalline phase of a
molecular dispersion or a solid solution state in the polymer
matrix. In this case, the change in thermoanalytical profile
indicates a strong interaction in function of the heating,
attributed to drug dissolution in melted polymer. Similar
results with others hydrophobic drugs encapsulated in
PLGA matrix were obtained by others authors (Venier-
Julienne, Benoit, 1996; Mu, Feng, 2002; Fitzgerald,
Corrigan, 1996).
The TG-DTA curves confirmed the data obtained by
DSC. Both empty and drug containing nanoparticles
present thermal stability in a lower temperature range
(200 °C) compared with the pure polymer (Figure 3 B and
3 C, respectively). The nanoparticles are more reactive than
the polymer due to their wider superficial area and,
consequently, they suffer thermal decomposition more
quickly. The weight loss of PRZ-nanoparticles occurs in
two steps (315 °C-69.35% and 520 °C-24.73%),
associated with exothermic events between the tempera-
tures of 200 °C and 550 °C. The TG-DTA curve of PRZ-
nanoparticles did not show any peak relative to the drug
melting point. Such fact was also confirmed by DSC,
reinforcing the idea that the drug were entrapped in the
nanoparticles in an amorphous state.
TABLE I - Encapsulation efficiency of PRZ-loaded PLGA
nanoparticles
Theoretical amount Encapsulation
of PRZ (% w/w) efficiency (%)
10 88 ± 3
20 073 ± 1.5
30 077 ± 3.5
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In the Figure 4, showing DSC curve of PRZ-
nanoparticles, the thermal pattern of the sample in an initial
time (first measure) is compared to that in the end time (4
months later, the sample was stored at room temperature).
Thermal changes were not observed during the period of the
time studied. This study suggests that no interaction that
could interfere in polymer and drug structure at the time
observed. In conclusion, no strong chemical interaction
between drug and polymer was observed. The nanoparticles
could be stored in room temperature with security.
Fourier Transform Infrared Studies (FTIR)
FTIR analysis measures the selective absorption
of light by the vibration modes of specific chemical
bonds in the sample. The observation of vibration
spectrum of encapsulated drug allows evaluating the
kind of interaction occurring between the drug and
polymer, because the vibrations of the atoms involved in
this interaction can suffer alterations in frequency and
intensity (Silverstein et al., 1994).
In the present work, one batch of prepared PRZ-
nanoparticles, pure PLGA, pure PRZ and physical
mixture of PLGA and PRZ were submitted to FTIR and
the spectra obtained are showed in Figure 5. The pure
PRZ sample (Figure 5 B) showed the main peaks
contributed by the functional groups of molecule such as
FIGURE 2 -  DSC curves obtained in dynamic air
atmosphere (100 mL/min) and heating rate 20 °C/min of
samples: A) pure PLGA; B) pure PRZ; C) physical mixture
PRZ/PLGA; D) empty nanoparticles and E) PRZ
nanoparticles.
FIGURE 3 - TG-DTA curves obtained in dynamic air atmosphere (100 mL/min) and heating rate 20 °C/min of samples:
A) pure PLGA; B) empty nanoparticles; C) PRZ nanoparticles and D) pure PRZ.
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carbonyl –C=O stretching (1630 cm-1), –CH, –CH2, –CH3
stretching (2900-3000 cm-1), –C–N stretching (1000-
1350 cm-1). The pure PLGA sample (Figure 5 A) showed
peaks such as –CH, –CH2, –CH3 stretching (2850-3000
cm-1), carbonyl –C=O stretching (1700-1800 cm-1), C–O
stretching (1050-1250 cm-1), and –OH stretching (3200-
3500 cm-1), which were broad. The physical mixture (Fi-
gure 5 C) and PRZ-loaded nanoparticles (Figure 5 D)
showed peaks resulting from simple superposition of their
separated components in the infrared spectra. In the
region of low wavelength the peaks cannot be so perfectly
observed because of the low drug concentration in the
nanoparticles. The spectral analysis indicated that the
specific functional groups of polymeric material in the
nanoparticles surface have almost the same chemical
characteristics of the pure polymer and the drug entrapped
shows their main characteristics peaks. The study
suggests that did not occur molecular interactions that
could alter the chemical structure of the drug in the time
of study.
CONCLUSIONS
The Tg of PLGA is above the physiological tempera-
ture of 37 °C and hence  it is glassy in nature. Thus, they
have a fairly rigid chain structure, which gives significant
mechanical strength usefull to drug delivery devices.
The thermoanalytical study suggests that PRZ is in an
amorphous state or in disordered crystalline phase of a
molecular dispersion in the PLGA polymeric matrix. The
relaxation enthalpy of PLGA was not influenced by the
FIGURE 5 - Infrared spectra of: A) pure PLGA; B) pure
PRZ; C) physical mixture PRZ/PLGA and D) PRZ
nanoparticles.
FIGURE 4 -  DSC curves obtained in dynamic air
atmosphere (100 mL/min) and heating rate of 20 °C/min of
PRZ nanoparticles: A) sample recently prepared; B) sample
stored for four months.
procedure used. The thermal stability was evaluated, and since
that all materials analyzed did not suffered appreciable
decomposition below 200 °C in the analytical conditions used,
it can be suggested that they can be safely processed using
some thermal treatment. The thermoanalytical results
corroborated the infrared studies, showing that strong
chemical interactions between PLGA and PRZ did not occur,
in the length of time studied. According to that, all results
obtained suggested that the microencapsulation process did not
interfere with the chemical structure of the polymer and keeps
the structural drug integrity. Thus, the methods employed to
produce and to characterize samples seem to be adequate.
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RESUMO
Estudo termoanalítico de nanopartículas de PLGA
contendo praziquantel
Nanopartículas poliméricas têm recebido grande atenção
como potenciais sistemas de liberação controlada de
fármacos. Polímeros biodegradáveis são extensivamente
usados no desenvolvimento destes sistemas e os poliéste-
res como ácido poli-láctico e o glicólico, e seus
copolímeros, como o ácido poli(láctico-co-glicólico) são
os mais usados considerando sua biocompatibilidade e
biodegradação. Técnicas de análise térmicas são usadas
para substâncias farmacêuticas há mais de 30 anos e são
métodos rotineiros para investigação de interações
fármaco-excipiente. O objetivo deste trabalho é usar aná-
lise térmica para caracterizar nanopartículas de PLGA
contendo um fármaco hidrofóbico, o praziquantel. Os re-
sultados mostram que o fármaco apresenta-se em estado
amorfo ou em fase cristalina desordenada de dispersão
molecular na matriz polimérica e que o processo de
microencapsulação não interfere na estrutura química do
polímero e manteve a integridade estrutural do fármaco.
UNITERMOS: Nanopartículas. Praziquantel. PLGA.
DSC. TG-DTA. Espectroscopia no infravermelho.
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